Last €13.51 EUR
Change Today -0.34 / -2.45%
Volume 331.6K
ALM On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
Continuous
As of 11:38 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

almirall sa (ALM) Snapshot

Open
€13.86
Previous Close
€13.85
Day High
€13.86
Day Low
€13.50
52 Week High
11/25/14 - €13.90
52 Week Low
04/16/14 - €10.60
Market Cap
2.3B
Average Volume 10 Days
714.1K
EPS TTM
€-0.07
Shares Outstanding
173.0M
EX-Date
05/19/14
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALMIRALL SA (ALM)

Related News

No related news articles were found.

almirall sa (ALM) Related Businessweek News

No Related Businessweek News Found

almirall sa (ALM) Details

Almirall, S.A., a pharmaceutical company, researches, develops, produces, and markets proprietary and licensed medicines worldwide. The company offers its products for dermatological diseases comprising psoriasis, eczema, and actinic keratosis; and gastrointestinal diseases, such as irritable bowel syndrome, as well as for pain. Its products include LAS41004, a compound that is in Phase II clinical trials for the treatment of psoriasis and/or atopic dermatitis; and LAS41008, which is in Phase III clinical trials for treating psoriasis. The company’s products also comprise Sativex, an oromucosal spray is in Phase III clinical trials for the treatment of spasticity in patients with multiple sclerosis; and LAS41002 for the treatment of inflammatory skin conditions. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Founded in 1943

almirall sa (ALM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

almirall sa (ALM) Key Developments

Almirall Reports Earnings Results for the Nine Months Ended September, 2014

Almirall has reported revenue growth up 7% year on year to EUR 654.1 million (USD 816.5 million) in the nine months to September, primarily driven by leading COPD treatment Eklira (aclidinium bromide), as well as its respiratory portfolio and dermatology franchise. Net profit accounted for EUR 42.9 million, a 96.8% increase compared to EUR 21.8 million in the equivalent period of 2013. EBITDA amounted to EUR 107 million, equating to an 80.4% increase compared with the same period last year.

Almirall, S.A. Presents at Kepler Cheuvreux Autumn Conference 2014, Sep-18-2014

Almirall, S.A. Presents at Kepler Cheuvreux Autumn Conference 2014, Sep-18-2014 . Venue: Paris, France. Speakers: Jordi Molina Alsina, Head of Investor Relations.

Almirall, S.A. Announces Financial Results for the Second Quarter Ended June 30, 2014; Reiterates Full-Year Earnings Guidance of 2014

Almirall, S.A. announced financial results for the second quarter ended June 30, 2014. For the quarter, the company reported net income of €8.5 million, compared to €7.4 million for the same quarter ended June 30, 2013. Total revenue for the second quarter ended June 30, 2014 was €215.8 million, compared to €212.1 million for the same quarter ended June 30, 2013. The positive trend seen in first quarter has continued in second quarter. It is especially to see the performance of Platforms of Growth (63% growth year on year and now representing 44% of sales), and the continuous strong gross margin evolution. This, combined with a lower expense trend in the second half of the year, will drive an expected acceleration of normalized net income growth through 2014 and gives the confidence to reiterate full-year guidance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALM:SM €13.51 EUR -0.34

ALM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cubist Pharmaceuticals Inc $75.65 USD +0.69
Ipsen SA €41.85 EUR -0.275
Orion Oyj €27.96 EUR -0.17
Recordati SpA €13.82 EUR 0.00
Synergy Health PLC 1,926 GBp +3.00
View Industry Companies
 

Industry Analysis

ALM

Industry Average

Valuation ALM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 2.5x
Price/Cash Flow 42.2x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALMIRALL SA, please visit www.almirall.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.